The association between BMI and BSA–temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525

BACKGROUND: Fearing increased myelotoxicity, many practitioners adjust the body surface area (BSA)-calculated doses in obese patients. Regarding temozolomide (TMZ), a prior study suggested men with a BSA >2 m(2) may experience increased toxicity; however, surprisingly, the inverse observation was...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neurooncol Pract
Asıl Yazarlar: Robins, H Ian, Eickhoff, Jens, Gilbert, Mark R, Armstrong, Terri S, Shi, Wenyin, De Groot, John F, Schultz, Christopher J, Hunter, Grant K, Valeinis, Egils, Roach, Mack, Youssef, Emad F, Souhami, Luis, Howard, Steve P, Lieberman, Frank S, Herman, James G, Zhang, Peixin, Mehta, Minesh P
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6899045/
https://ncbi.nlm.nih.gov/pubmed/31832217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nop/npz006
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller